Navigation Links
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
Date:9/2/2008

NATICK, Mass. and Munich, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the European and Intercontinental launch phases of its global TAXUS OLYMPIA registry, the world's largest post-approval, prospective registry for a single drug-eluting stent (DES). OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease. Results from the 22,000-patient study were presented by Oscar Mendiz, M.D., at the European Society of Cardiology Congress in Munich, Germany.

The TAXUS OLYMPIA registry employs a consecutive enrollment process and consists of diverse and high-risk patient populations, reflecting real-world usage patterns found in everyday clinical practice. One-year data were collected for a total of 22,345 patients to date in 57 countries. A large majority of patients (75%) were considered "expanded use" cases consisting of complex lesions or complex clinical characteristics. The overall OLYMPIA population in these two phases included patients with multivessel disease (56.5%), prior PCI (27.9%), prior myocardial infarction (MI) (34.1%), multiple stents (32.3%), and medically treated diabetes (27.0%).

The one-year results demonstrated a low overall 3.8 percent rate of TAXUS Liberte stent-related composite cardiac events, including cardiac death (1.2%), MI (0.8%), and re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is consistent with safety data from other DES registries. In the more complex expanded use patient population, the rates
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
3. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the following conferences. , Deutsche Bank ... May 29, 2013 , Presentation time: 12:00 p.m. P.T. ... , Presentation date: Wednesday June 5, 2013 , Presentation ... A live webcast and 30-day archive of these presentations will ...
(Date:5/22/2013)...  Grifols, a global healthcare company based in ... study demonstrating that a higher dose of PROLASTIN © ... the alpha 1 protein in patients with alpha ... within the normal range for healthy individuals. AAT deficiency ... of the alpha 1 proteinase inhibitor (A1PI) protein ...
(Date:5/22/2013)... LAKE CITY , May 22, 2013 /PRNewswire/ ... ) today announced it received 510(k) clearance from ... Varian,s diagnostic X-ray image processing workstation that combines ... on one platform.  Varian,s Nexus DRF Digital X-Ray ... a variety of image receptors, including CCD cameras ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2
... designed for more uniform drug ... ... Boston,Scientific Corporation (NYSE: BSX ) today announced comprehensive data ... historically controlled trials, which evaluate,the TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent System in ...
... with Kogenate FS Reduces the,Risk of Joint Damage ... Damage, BERKELEY, Calif., Oct. 10 Bayer ... Drug Administration (FDA) has,approved routine prophylaxis with Kogenate(R) ... bleeding episodes and the risk of,joint damage in ...
Cached Medicine Technology:Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:5/22/2013)... 22, 2013 Mari’s Skin Care, a peaceful ... the first in the state of Texas to offer a ... Medical and Esthetic Tissue Activation, also known as collagen ... years in Europe, but has just recently made its way ... skin from inside out by building collagen and elastin. ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 The ... (Amino Resins, Melamine Formaldehyde, Melamine Urea Formaldehyde), Applications ... - Global Trends and Forecasts to 2018" defines ... forecasting of the global volume and revenue. ... for the Global Amino Resins Market with analysis ...
(Date:5/21/2013)... May 22, 2013 Spring is the ... nutrition--from farmers' markets filled with whole foods to weather ... most of the season the nutrition experts at Brilliant ... not to miss. , 1. Eating Locally, With the ... shoppers to linger and explore, spring is a great ...
(Date:5/21/2013)... May 21, 2013 Heritage Woods of ... BMA affordable assisted living community, is hosting a Quality Home ... at 2 p.m. on Tuesday, May 28. , The community, ... serves older adults of all incomes, including those on Medicaid, ... Arthritis program is open to the public. There is ...
(Date:5/21/2013)... Standard advice for mattress shoppers often consists ... given industry’s less than exceptional satisfaction ratings and the ... Consumer Mattress Reports sets out to revise this advice ... .” , This article addresses several components of the ... not be readily apparent to many shoppers. From prices ...
Breaking Medicine News(10 mins):Health News:Mari's to Offer New Treatment from Europe 2Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 2Health News:Asia-Pacific Leads in Consumption of Urea Formaldehyde Resins Followed by Europe and North America - New Report by MarketsandMarkets 3Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2
... News) -- Adding more weight to concerns about possible ... people who take the drugs, known as bisphosphonates, may be ... (femur). Osteoporosis is a bone-thinning disease that is ... unusual type of break that often occurs spontaneously, without any ...
... team of researchers, including a scientist from the Viral ... a type of herpesvirus infection of the eye is ... that causes blindness in the elderly. The scientists ... the production of vascular endothelial growth factor, or VEGF, ...
... 2012) Behavioral support from peers and primary care office ... as much as starting a new drug, a new study ... Medicine San Antonio, is the senior author. The randomized, ... support from peers and primary care office staff could ...
... (HealthDay News) -- Men with severe gum disease, known as ... new study that finds young men and the elderly at ... a large study to identify almost 33,000 men with ... condition. Of these study participants, about 12 percent ...
... quality of care you receive be affected by how your ... at Brigham and Women,s Hospital (BWH), doctors who dictated their ... who used structured documentation. The study is published ... Association . The researchers evaluated 18,569 visits by 7,000 ...
... Spanish . Flexible sigmoidoscopy, a screening ... fewer side effects than colonoscopy, is effective in reducing the ... according to research sponsored by the National Cancer Institute, part ... that spanned almost 20 years, researchers found that overall colorectal ...
Cached Medicine News:Health News:More Research Points to Long-Term Ills With Bone Drugs 2Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Severe Gum Disease, Impotence May Be Linked 2Health News:To dictate or not to dictate? 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 3Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 4
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: